Ticker

New York, New York--(Newsfile Corp. - March 6, 2026) - Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at Unicycive Therapeutics caused the company to misrepresent or fail to disclose that: (i) Unicycive's…

Philadelphia, Pennsylvania--(Newsfile Corp. - February 17, 2026) - WHAT IS HAPPENING? Grabar Law Office is investigating claims on behalf of shareholders of Unicycive Therapeutics, Inc. (NASDAQ: UNCY).

LOS ALTOS, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer, will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit on Wednesday, February 11, 2026, at 1:30…

I initiate Unicycive Therapeutics with a "Buy" rating, driven by the FDA's acceptance of its OLC NDA resubmission and a defined PDUFA date. OLC targets hyperphosphatemia in CKD dialysis patients, offering competitive advantages like lower pill burden, smaller size, and swallowable tablets. The prior FDA rejection was solely due to third-party manufacturing issues, not clinical data, increasing confidence in…

FDA assigns Prescription Drug User Fee Act (PDUFA) target date of June 29, 2026 Ended 2025 with unaudited cash position of $41.3M with expected runway into 2027 LOS ALTOS, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that the U.S. Food…